These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27476490)

  • 21. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine.
    Ramos-Quiroga JA; Corominas-Roso M; Palomar G; Gomez-Barros N; Ribases M; Sanchez-Mora C; Bosch R; Nogueira M; Corrales M; Valero S; Casas M
    Psychopharmacology (Berl); 2014 Apr; 231(7):1389-95. PubMed ID: 24202115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Cardo E; Porsdal V; Quail D; Fuentes J; Steer C; Montoya A; Anand E; Escobar R
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):252-61. PubMed ID: 23683140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine.
    Sobanski E; Sabljic D; Alm B; Dittmann RW; Wehmeier PM; Skopp G; Strohbeck-Kühner P
    Eur Psychiatry; 2013 Aug; 28(6):379-85. PubMed ID: 23062837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder.
    Yamamuro K; Ota T; Iida J; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto N; Tanaka S; Kishimoto T
    Psychiatry Res; 2016 Aug; 242():288-294. PubMed ID: 27318633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study.
    Meyers KJ; Upadhyaya HP; Goodloe R; Kryzhanovskaya LA; Liles-Burden MA; Kellier-Steele NA; Mancini M
    Expert Opin Drug Saf; 2018 May; 17(5):467-473. PubMed ID: 29625537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).
    Pohl GM; Van Brunt DL; Ye W; Stoops WW; Johnston JA
    BMC Health Serv Res; 2009 Jun; 9():95. PubMed ID: 19505334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
    Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice.
    Marchei E; Papaseit E; Garcia-Algar O; Bilbao A; Farré M; Pacifici R; Pichini S
    Drug Test Anal; 2013 Mar; 5(3):191-5. PubMed ID: 22991172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.
    Kole IH; Vural P; Yurdacan B; Alemdar A; Mutlu C
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1773-1785. PubMed ID: 39158690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
    Schwartz S; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of factors associated with the efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder.
    Nagai T; Kurihara T; Koya H; Nakano Y; Sugisawa S; Sambe T; Kishimoto K; Kogo M; Ota H; Iwanami A; Uchida N
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):249-255. PubMed ID: 35485452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.